STOCK TITAN
  1. Home
  2. News
  3. CSTL

Castle Biosciences - CSTL STOCK NEWS

Welcome to our dedicated page for Castle Biosciences news (Ticker: CSTL), a resource for investors and traders seeking the latest updates and insights on Castle Biosciences stock.

Castle Biosciences, Inc. (symbol: CSTL) is a pioneering company specializing in diagnostic tests for a variety of cancers. Founded in 2008, Castle Biosciences has dedicated itself to advancing cancer care through objective and accurate testing. The company's primary mission is to provide physicians and patients with personalized, clinically actionable genomic information to facilitate more precise treatment decisions.

Castle Biosciences offers a range of diagnostic tests that assist doctors in the treatment of various cancers. Their current product portfolio includes tests for cutaneous melanoma, uveal melanoma, esophageal adenocarcinoma, mesothelioma, and glioma. Notably, their products include DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME, all designed to provide vital information that can influence the course of cancer treatment.

The company is not just limited to its existing portfolio; it actively engages in research programs aimed at developing diagnostic tests for other under-served cancers, such as rectal cancer and soft tissue sarcoma. These initiatives underscore Castle Biosciences' commitment to addressing gaps in cancer diagnostics and improving patient outcomes.

Castle Biosciences collaborates closely with leading members of the oncology community to ensure that their tests are both innovative and clinically relevant. This collaboration spans the discovery, development, and practical utilization of their diagnostic tests, reinforcing their standing as a crucial player in the field of cancer diagnostics.

The company is currently in a robust financial condition, reflecting its successful commercialization efforts and consistent revenue growth. Recent achievements include expanding their test portfolio and forging strategic partnerships aimed at broadening their market reach and enhancing their technological capabilities.

For the latest updates and detailed information on Castle Biosciences, Inc. and its products, please visit their official website at www.castlebiosciences.com.

News

Castle Biosciences to Present at Upcoming Investor Conferences

Rhea-AI Summary
Castle Biosciences, Inc. (CSTL) to Present Company Overview at Investor Conferences in November 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.22%
Tags
conferences
-
News

Castle Announces Early Exploratory Study Data for Potential Development of a Complementary Test to Accompany DecisionDx®-UM That Could Aid in the Early Detection of Uveal Melanomas

Rhea-AI Summary
Castle Biosciences, Inc. announced new discovery data from a study exploring the potential for developing a complementary test to evaluate small, suspicious lesions of uncertain malignant potential in patients' eyes. The data will be presented at the 2023 American Academy of Ophthalmology Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.99%
Tags
none
-
News

Early Discovery Data Shows Ability of Castle Biosciences’ Pipeline Program to Distinguish Between Responders and Non-Responders to an Atopic Dermatitis Therapy

Rhea-AI Summary
Castle Biosciences, Inc. plans to launch a genomic test by the end of 2025 that can guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis, psoriasis, and related conditions. New data shows the test's ability to distinguish between responders and non-responders to an atopic dermatitis therapy, as well as differentiate between atopic dermatitis, psoriasis, and mycosis fungoides skin lesions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.99%
Tags
none
News

Castle Biosciences Reports Third Quarter 2023 Results

Rhea-AI Summary
Castle Biosciences reports exceptional Q3 2023 results with a 66% increase in revenue to $61.5 million and a 52% increase in total test reports. They raise their full-year 2023 revenue guidance to at least $200 million from $180 million. Gross margin for Q3 was 78% and adjusted gross margin was 81%. Net cash provided by operations was $5.0 million, and adjusted EBITDA was $6.6 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.99%
Tags
earnings
-
News

Castle Biosciences to Present New Data on its TissueCypher® Barrett’s Esophagus Test at the 2023 American College of Gastroenterology Annual Scientific Meeting

Rhea-AI Summary
Castle Biosciences will highlight the risk stratification capabilities of its TissueCypher test for patients with Barrett's esophagus at the ACG 2023 Annual Scientific Meeting. The test can identify higher- and lower-risk subsets of patients, providing objective risk stratification that can help guide patient care and potentially prevent cancer diagnosis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.28%
Tags
conferences
-
News

Persephone Biosciences Appoints Daniel Bradbury as Chair of the Board of Directors

Rhea-AI Summary
Persephone Biosciences appoints Daniel Bradbury as Chair of the Board of Directors
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
News

Castle Biosciences to Release Third Quarter 2023 Financial Results and Host Conference Call on Thursday, Nov. 2

Rhea-AI Summary
Castle Biosciences to release financial results for Q3 and nine months ended Sept. 30, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.69%
Tags
earnings
-
News

New Data Highlights Clinical Utility and Performance of Castle Biosciences’ Dermatologic Test Portfolio at the 2023 Fall Clinical Dermatology Conference®

Rhea-AI Summary
Castle Biosciences to share new data on gene expression profile tests at Fall Clinical Dermatology Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.69%
Tags
none
-
News

DecisionDx®-Melanoma Outperforms Memorial Sloan Kettering Cancer Center (MSKCC) Nomogram in Predicting Sentinel Lymph Node Positivity in Patients with Cutaneous Melanoma

Rhea-AI Summary
Study shows DecisionDx-Melanoma test outperforms MSKCC nomogram in predicting risk of SLN positivity in patients with melanoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.57%
Tags
none
News

Castle Biosciences Presents New Data at ASTRO 2023 Highlighting Risk-Stratification Performance of DecisionDx®-SCC in Patients with Cutaneous Squamous Cell Carcinoma Eligible for Adjuvant Radiation Therapy

Rhea-AI Summary
Castle Biosciences, Inc. will present new data at the ASTRO 2023 Annual Meeting demonstrating the ability of its DecisionDx®-SCC test to identify node-negative cutaneous squamous cell carcinoma (SCC) patients at a higher risk of metastasis who may benefit from adjuvant radiation therapy (ART). The test significantly stratified the cohort according to risk of metastasis, with metastasis-free survival rates of 92.4%, 76.1%, and 59.4% for patients with Class 1, Class 2A, and Class 2B test results, respectively. This could guide risk-aligned treatment decisions and potentially de-intensify treatment for some patients. Abstracts will be published in the International Journal of Radiation Oncology • Biology • Physics (Red Journal).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.75%
Tags
none

FAQ

What is the current stock price of Castle Biosciences (CSTL)?

The current stock price of Castle Biosciences (CSTL) is $26.04 as of February 26, 2025.

What is the market cap of Castle Biosciences (CSTL)?

The market cap of Castle Biosciences (CSTL) is approximately 702.7M.

What does Castle Biosciences specialize in?

Castle Biosciences specializes in diagnostic tests for various cancers, providing genomic information to aid in treatment decisions.

When was Castle Biosciences founded?

Castle Biosciences was founded in 2008.

What types of cancer does Castle Biosciences have tests for?

Castle Biosciences has tests for cutaneous melanoma, uveal melanoma, esophageal adenocarcinoma, mesothelioma, and glioma.

What are some of Castle Biosciences' notable products?

Notable products include DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME.

Is Castle Biosciences involved in research for new diagnostic tests?

Yes, they have active research programs in rectal cancer and soft tissue sarcoma, among others.

Where can I find more information about Castle Biosciences and its products?

You can visit their official website at www.castlebiosciences.com for more detailed information.

What is the primary mission of Castle Biosciences?

The primary mission is to provide personalized, clinically actionable genomic information to make more accurate treatment decisions.

Does Castle Biosciences collaborate with other entities?

Yes, they work closely with outstanding members of the oncology community throughout the discovery, development, and utilization of their tests.

What is Castle Biosciences' financial condition?

The company is in a robust financial condition, reflecting successful commercialization efforts and consistent revenue growth.

How does Castle Biosciences contribute to cancer care?

By providing objective and accurate diagnostic tests, Castle Biosciences helps advance cancer care and improve patient outcomes.
Stock CSTL logo
Castle Biosciences

Nasdaq:CSTL

CSTL Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

CSTL Stock Data

702.70M
27.07M
3.37%
94.78%
5.97%
Diagnostics & Research
Services-medical Laboratories
Link
United States
FRIENDSWOOD